Walvax subsidiary gains approval for shingles mRNA vaccine trial

Yunnan Walvax Biotechnology Co., Ltd. announced that its subsidiary, Beijing Walvax Innovation Biotechnology Co., Ltd., along with partners Fudan University and Shanghai Blue Whale Biopharmaceuticals Co., Ltd., has received approval for clinical trials of its lyophilized varicella-zoster virus mRNA vaccine for shingles. The approval covers a biological product for prevention, stating the vaccine meets registration requirements to proceed with clinical trials for preventing herpes zoster.

The vaccine, developed on an independently established mRNA vaccine technology platform, is designed to stimulate the body's immune response against the shingles virus. Its innovative antigen sequence design and structural modifications aim to induce high-level antibody and cellular immune responses, incorporating several innovations compared to currently published patents for major shingles vaccines.

The company notes this clinical trial approval will not significantly impact its performance for the current year. However, the progress and results of clinical studies, as well as the timing for market application and approval, are subject to uncertainties. Investors are cautioned to exercise prudence given the inherent investment risks.